dmb2,
Thanks for the support and you may be correct about the FDA issue, however, my focus has been on how NWBO might have been able to reign in the bad actors with regard to the reason for the screening hold. Mr. Woodford pointed to it when he said it was a bump in the road and part of the expected process. To me that means conversion from artisan to more closed system. The fact that NWBO started looking to develop this in 2014 and Mr. Woodford made this comment in 2015 tells me that there were early struggles with trying to get Flaskworks going and was going to take more time than originally expected to develop. This led to NWBO purchasing clean rooms in 2015 perhaps thinking that they would be able to get them operational a couple of years later to help with potential Specials demand and eventual comparability studies. By 2018 it had become clear perhaps that Specials was not going to be a good source of income and Flaskworks development had probably stalled somewhat since Linda openly asked for help developing manufacturing from anyone interested at the ASM that year as I recall. No one came to the rescue but 6 years later Flaskworks was headed towards their first GMP model which then was delayed in favor of developing units with a smaller footprint. We now sit 6 months past that time with hopes for approval soon, an update on Flaskworks and perhaps a development deal. Manufacturing issues and approval have been quietly merging toward one another all during this time.
Bottom line is all the development time could have been used even more effectively to kill interest in this stock if more bad actors with inside info would have been allowed to trade the stock based on unknown time frame development delays and longs knew how long they would need to wait. Many more shares would have been traded out with the hope to buy back cheaper only to find out that bankruptcy would likely have been the end result because of the help given to the bad actors by unsuspecting investors. Best wishes.
Market Data 
Markets 
AI
